Valuation: Nexstim Oyj

Market Cap 76.63M 87.22M 71.05M 65.34M 123M 8.34B 126M 848M 331M 4.1B 327M 320M 14.17B P/E 2026 *
79.1x
P/E 2027 * 35.1x
Enterprise Value 74.53M 84.83M 69.1M 63.55M 120M 8.12B 123M 824M 322M 3.98B 319M 312M 13.78B EV / Sales 2026 *
5.87x
EV / Sales 2027 * 4.53x
Free-Float
58.2%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 49 11/02/2020
Director of Finance/CFO 40 11/02/2020
Chief Tech/Sci/R&D Officer 65 01/01/2008
Director TitleAgeSince
Director/Board Member 64 11/11/2019
Chairman 63 11/11/2019
Director/Board Member 55 01/05/2021
Change 5-day change 1-year change 3-year change Capi.($)
-6.90%-5.73% - - 90.65M
+0.28%+0.97%+21.54%+0.49% 196B
+0.08%-4.43%-20.49%+17.13% 144B
+0.56%+1.13%-2.29%-15.94% 141B
-0.27%-1.09%-56.73%-14.89% 66.54B
-0.46%-2.73%+17.60%-1.41% 53.09B
+2.80%+1.69%-22.83%-29.39% 44.12B
-0.19%+2.56%+8.73%+11.70% 37.93B
-0.85%-1.60%+5.76%+38.77% 36.96B
+0.94%-0.39%-13.07%-20.05% 29.43B
Average -0.40%-0.75%-6.87%-1.51% 83.21B
Weighted average by Cap. +0.29%-0.83%-3.67%-1.01%

Financials

2026 *2027 *
Net sales 12.7M 14.46M 11.77M 10.83M 20.45M 1.38B 20.89M 140M 54.93M 679M 54.28M 53.09M 2.35B 16.1M 18.33M 14.93M 13.73M 25.93M 1.75B 26.48M 178M 69.64M 860M 68.81M 67.3M 2.98B
Net income 1M 1.14M 927K 853K 1.61M 109M 1.64M 11.06M 4.33M 53.45M 4.27M 4.18M 185M 2.2M 2.5M 2.04M 1.88M 3.54M 240M 3.62M 24.33M 9.52M 118M 9.4M 9.2M 407M
Net Debt -2.1M -2.39M -1.95M -1.79M -3.38M -229M -3.45M -23.23M -9.08M -112M -8.97M -8.78M -388M -3.7M -4.21M -3.43M -3.15M -5.96M -403M -6.09M -40.93M -16M -198M -15.81M -15.47M -684M
Logo Nexstim Oyj
Nexstim Oyj is a Finland-based medical technology company. It is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-